CAMBRIDGE-BLOCKCHAIN
16.7.2019 12:02:09 CEST | Business Wire | Press release
LuxTrust S.A., a leading Digital Trust Services Provider in Luxembourg, and Cambridge Blockchain Inc. , a pioneer in digital identity enterprise Software, announced the private beta-testing phase for privacy-protecting European identity platform IDKEEP .
Designed to resolve identity and personal-data related challenges faced by many digital service providers — such as banks and financial services, insurance, and healthcare, among others—IDKEEP is a huge step forward towards data ownership and control. The platform provides end users with full control over personal data and over sharing such data with services online, helping digital organizations to effectively manage consent as per GDPR rules and effectively manage validated users’ data, enabling trusted transactions online. In addition, IDKEEP opens a marketplace for data validators who can leverage a network effect of a large customer base, realizing efficiencies and re-use of expensive data validation processes.
IDKEEP was developed by LuxTrust in Luxembourg to augment the intrinsic value of existing digital identities which already take up the entire population of the country, and to foster a data-driven business ecosystem. With IDKEEP, LuxTrust combines its role of eIDAS Qualified Trust Services Provider, with a GDPR trusted third-party role. Supported by the Luxembourg State, one of company’s shareholders as well as a strategic partnership with InfoCert (Italy), IDKEEP leads the way towards a new age of digital identity.
IDKEEP has been showcased in Seoul, South Korea today, in presence of Luxembourg’s Deputy Prime Minister and Minister of the Economy, Étienne Schneider, thereby initiating a beta-testing phase. Étienne Schneider said: “With the introduction of its IDKEEP solution, LuxTrust shows off its skills and competencies when it comes to play a leading role as an innovation-driven company. The platform asserts LuxTrust’s position as a forerunner among digital identity providers. Technological developments like IDKEEP help to achieve the digital economy of tomorrow and contribute to Luxembourg’s reputation in Europe and beyond as a trusted data hub”.
IDKEEP platform runs on Cambridge Blockchain’s innovative blockchain-based enterprise software, a first-of-its-kind technology that gives users back control of their own identity by increasing data quality, re-usability, and trust. “After receiving investments from PayPal (NASDAQ:PYPL ), Flourish and Omidyar Network earlier this year, we are pleased to continue our expansion to deliver the future of digital identity for Europe and beyond.” said Matthew Commons, CEO and cofounder of Cambridge Blockchain.
This announcement is an important milestone toward the resolution of digital identity challenges. IDKEEP is now signing up additional trusted parties and service providers. Organizations interested in joining the platform should please contact Povilas Žinys: povilas.zinys@luxtrust.lu
View source version on businesswire.com: https://www.businesswire.com/news/home/20190716005351/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom